quinidine

REMS

Restoration and maintenance of sinus rhythm in patients with atrial fibrillation or flutter.
Prevention of recurrent ventricular arrhythmias.
Treatment of malaria.

Contraindicated in:

Hypersensitivity
Conduction defects (in the absence of a pacemaker)
Myasthenia gravis.

Use Cautiously in:

HF (dose reduction recommended)
Severe liver disease (dose ↓ recommended)
Hypokalemia or hypomagnesemia (↑ risk of torsades de pointes)
Bradycardia (↑ risk of torsades de pointes)
Renal impairment
OB: Lactation: Pedi: Safety not established; extended-release preparations should not be used in children.

CNS: dizziness, confusion, fatigue, headache, syncope, vertigo.

EENT: blurred vision, diplopia, mydriasis, photophobia, tinnitus.

CV: HYPOTENSION, TORSADES DE POINTES, arrhythmias, palpitations, tachycardia.

GI: anorexia, abdominal cramping, diarrhea, nausea, vomiting, drug-induced hepatitis.

Derm: rash.

Hemat: AGRANULOCYTOSIS, hemolytic anemia, thrombocytopenia.

Neuro: ataxia, tremor.

Misc: fever.

Drug-Drug:

May ↑ risk of QT interval prolongation when used with tricyclic antidepressants, erythromycin, clarithromycin, haloperidol, sotalol, or fluoroquinolones.
↑serum digoxin levels and may cause toxicity (dose reduction recommended).
Phenytoin, phenobarbital, carbamazepine, or rifampin may ↑ metabolism and ↓ effectiveness.
Cimetidine, diltiazem, verapamil, amiodarone, ketoconazole, itraconazole, and protease inhibitors↓ metabolism and may ↑ blood levels.
Excretion is delayed and effects ↑ by drugs that alkalinize the urine, including carbonic anhydrase inhibitors, thiazide diuretics, and sodium bicarbonate.
Potentiates the effects of neuromuscular blocking agents and warfarin.
Additive hypotension with antihypertensives, nitrates, and acute ingestion of alcohol.
May ↑ procainamide, haloperidol, mexiletine, or tricyclic antidepressant levels and risk of toxicity.
May antagonize anticholinesterase therapy in patients with myasthenia gravis.
Additive anticholinergic effects may occur with agents having anticholinergic properties (including antihistamines, tricyclic antidepressants).

Drug-Food:

Grapefruit juice↑ serum levels and effect (avoid concurrent use).
Foods that alkalinize the urine (see Appendix M) may ↑ serum quinidine levels and the risk of toxicity.

(Generic available)

Quinidine Gluconate

Extended-release tablets: 324 mg;

Quinidine Sulfate

Tablets: 200 mg; 300 mg;
Extended-release tablets: 300 mg;
In combination with: dextromethorphan (Nuedexta); see Appendix [not included in this PDA edition].

Quinidine Gluconate (62% Quinidine)

PO (Adults): 324–972 mg q 8–12 hr.

Quinidine Sulfate (83% Quinidine)

PO (Adults): Atrial/ventricular arrhythmias — 200–400 mg q 4–6 hr; may be ↑ to achieve therapeutic response (not to exceed 3–4 g/day).
PO (Children): 6 mg/kg 4–5 times daily.

Decrease myocardial excitability.
Slow conduction velocity.

Therapeutic Effects:

Suppression of arrhythmias.

Therapeutic Classification: antiarrhythmics (class IA)

Absorption: Bioavailability of oral formulations is 70–80%. Extended-release preparations are absorbed slowly following oral administration.

Distribution: Widely distributed. Cross the placenta; enter breast milk.

Metabolism/Excretion: Metabolized by the liver; 5–20% excreted unchanged by the kidneys.

Half-life: 6–8 hr (↑ in HF or severe liver impairment).

(antiarrhythmic effects)

ROUTE	ONSET	PEAK	DURATION
PO (sulfate)	30 min	1–1.5 hr	6–8 hr
PO (sulfate-ER)	unknown	4 hr	8–12 hr
PO (gluconate)	unknown	3–4 hr	6–8 hr

Instruct patient to take medication around the clock, exactly as directed, even if feeling well. Take missed doses as soon as remembered if within 2 hr; if remembered later, omit. Do not double doses.
Instruct patient or family member on how to take pulse. Advise patient to report changes in pulse rate or rhythm to health care professional.
May cause dizziness or blurred vision. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
Inform patient that quinidine may cause increased sensitivity to light. Dark glasses may minimize this effect.
Advise patient to inform health care professional of medication regimen prior to treatment or surgery.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and consult health care professional before taking any new medications.
Advise patient to consult health care professional if symptoms of cinchonism, rash, or dyspnea occur or if diarrhea is severe or persistent.
Advise patient to carry identification at all times describing disease process and medication regimen.
Advise female patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.
Emphasize the importance of routine follow-up exams to monitor progress.

KWIN-i-deen

quinidine gluconate: KWIN-i-deen GLUE-con-ate

quinidine sulfate: KWIN-i-deen SUL-fate

NDC Code^*

0185- Eon Labs, Inc.
0185-1047- Quinidine Sulfate 0185-1047-01- 100 TABLET in 1 BOTTLE (0185-1047-01)

0185- Eon Labs, Inc.
0185-4346- Quinidine Sulfate 0185-4346-01- 100 TABLET in 1 BOTTLE (0185-4346-01)

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Classifications ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

Code ⬆